Which has higher earnings and valuation, ENTX or FTH?

Entera Bio is trading at a lower price-to-earnings ratio than Sensei Biotherapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Entera Bio N/A N/A -$11.44M -$0.35 N/A Sensei Biotherapeutics N/A N/A -$21.08M -$141.65 N/A

Is ENTX or FTH more profitable?

Entera Bio's return on equity of -147.19% beat Sensei Biotherapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Entera Bio N/A -147.19% -103.22% Sensei Biotherapeutics N/A -1,012.17% -175.69%

Does the media prefer ENTX or FTH?

In the previous week, Sensei Biotherapeutics had 4 more articles in the media than Entera Bio. MarketBeat recorded 8 mentions for Sensei Biotherapeutics and 4 mentions for Entera Bio. Entera Bio's average media sentiment score of 0.80 beat Sensei Biotherapeutics' score of 0.44 indicating that Entera Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Entera Bio 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sensei Biotherapeutics 0 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to ADCT or FTH?

In the previous week, ADC Therapeutics had 2 more articles in the media than Sensei Biotherapeutics. MarketBeat recorded 10 mentions for ADC Therapeutics and 8 mentions for Sensei Biotherapeutics. ADC Therapeutics' average media sentiment score of 0.46 beat Sensei Biotherapeutics' score of 0.44 indicating that ADC Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ADC Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Sensei Biotherapeutics 0 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is IFRX or FTH more profitable?

InflaRx's return on equity of -53.56% beat Sensei Biotherapeutics' return on equity. Company Net Margins Return on Equity Return on Assets InflaRx N/A -53.56% -43.02% Sensei Biotherapeutics N/A -1,012.17% -175.69%

Does the media refer more to IFRX or FTH?

In the previous week, Sensei Biotherapeutics had 6 more articles in the media than InflaRx. MarketBeat recorded 8 mentions for Sensei Biotherapeutics and 2 mentions for InflaRx. InflaRx's average media sentiment score of 0.71 beat Sensei Biotherapeutics' score of 0.44 indicating that InflaRx is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment InflaRx 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sensei Biotherapeutics 0 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is FTH or EQ more profitable?

Equillium's return on equity of -41.15% beat Sensei Biotherapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Sensei Biotherapeutics N/A -1,012.17% -175.69% Equillium N/A -41.15% -38.29%

Does the media favor FTH or EQ?

In the previous week, Sensei Biotherapeutics had 1 more articles in the media than Equillium. MarketBeat recorded 8 mentions for Sensei Biotherapeutics and 7 mentions for Equillium. Equillium's average media sentiment score of 1.49 beat Sensei Biotherapeutics' score of 0.44 indicating that Equillium is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sensei Biotherapeutics 0 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Equillium 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation and earnings, NGEN or FTH?

NervGen Pharma is trading at a lower price-to-earnings ratio than Sensei Biotherapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NervGen Pharma N/A N/A -$31.58M -$0.09 N/A Sensei Biotherapeutics N/A N/A -$21.08M -$141.65 N/A

Is NGEN or FTH more profitable?

Sensei Biotherapeutics' return on equity of -1,012.17% beat NervGen Pharma's return on equity. Company Net Margins Return on Equity Return on Assets NervGen Pharma N/A -1,259.82% -199.79% Sensei Biotherapeutics N/A -1,012.17% -175.69%

Does the media prefer NGEN or FTH?

In the previous week, Sensei Biotherapeutics had 1 more articles in the media than NervGen Pharma. MarketBeat recorded 8 mentions for Sensei Biotherapeutics and 7 mentions for NervGen Pharma. Sensei Biotherapeutics' average media sentiment score of 0.44 beat NervGen Pharma's score of 0.13 indicating that Sensei Biotherapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NervGen Pharma 0 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Sensei Biotherapeutics 0 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Sensei Biotherapeutics (FTH) Competitors

$32.77 +0.43 (+1.33%)

As of 04:00 PM Eastern

Compare

FTH vs. ENTX, ADCT, IFRX, EQ, and NGEN

Should you buy Sensei Biotherapeutics stock or one of its competitors? Sensei Biotherapeutics's main competitors and comparable companies include Entera Bio (ENTX), ADC Therapeutics (ADCT), InflaRx (IFRX), Equillium (EQ), and NervGen Pharma (NGEN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Sensei Biotherapeutics compare to Entera Bio?

Entera Bio (NASDAQ:ENTX) and Sensei Biotherapeutics (NASDAQ:FTH) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, dividends, earnings, analyst recommendations, profitability, institutional ownership, valuation and risk.

In the previous week, Sensei Biotherapeutics had 4 more articles in the media than Entera Bio. MarketBeat recorded 8 mentions for Sensei Biotherapeutics and 4 mentions for Entera Bio. Entera Bio's average media sentiment score of 0.80 beat Sensei Biotherapeutics' score of 0.44 indicating that Entera Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Entera Bio	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Sensei Biotherapeutics	0 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Entera Bio is trading at a lower price-to-earnings ratio than Sensei Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Entera Bio	N/A	N/A	-$11.44M	-$0.35	N/A
Sensei Biotherapeutics	N/A	N/A	-$21.08M	-$141.65	N/A

Entera Bio has a beta of 1.38, meaning that its stock price is 38% more volatile than the broader market. Comparatively, Sensei Biotherapeutics has a beta of -0.25, meaning that its stock price is 125% less volatile than the broader market.

14.1% of Entera Bio shares are held by institutional investors. Comparatively, 10.5% of Sensei Biotherapeutics shares are held by institutional investors. 10.6% of Entera Bio shares are held by insiders. Comparatively, 7.0% of Sensei Biotherapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Entera Bio's return on equity of -147.19% beat Sensei Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Entera Bio	N/A	-147.19%	-103.22%
Sensei Biotherapeutics	N/A	-1,012.17%	-175.69%

Entera Bio presently has a consensus price target of $9.00, suggesting a potential upside of 210.34%. Sensei Biotherapeutics has a consensus price target of $54.90, suggesting a potential upside of 67.53%. Given Entera Bio's higher possible upside, analysts clearly believe Entera Bio is more favorable than Sensei Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Entera Bio	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Sensei Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83

Summary

Entera Bio beats Sensei Biotherapeutics on 9 of the 14 factors compared between the two stocks.

How does Sensei Biotherapeutics compare to ADC Therapeutics?

ADC Therapeutics (NYSE:ADCT) and Sensei Biotherapeutics (NASDAQ:FTH) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, dividends, media sentiment, risk, analyst recommendations, valuation and institutional ownership.

ADC Therapeutics currently has a consensus target price of $5.00, suggesting a potential upside of 358.72%. Sensei Biotherapeutics has a consensus target price of $54.90, suggesting a potential upside of 67.53%. Given ADC Therapeutics' higher probable upside, analysts clearly believe ADC Therapeutics is more favorable than Sensei Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ADC Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Sensei Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83

ADC Therapeutics has a beta of 1.89, indicating that its share price is 89% more volatile than the broader market. Comparatively, Sensei Biotherapeutics has a beta of -0.25, indicating that its share price is 125% less volatile than the broader market.

41.1% of ADC Therapeutics shares are held by institutional investors. Comparatively, 10.5% of Sensei Biotherapeutics shares are held by institutional investors. 5.1% of ADC Therapeutics shares are held by company insiders. Comparatively, 7.0% of Sensei Biotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Sensei Biotherapeutics has a net margin of 0.00% compared to ADC Therapeutics' net margin of -121.77%. ADC Therapeutics' return on equity of 0.00% beat Sensei Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ADC Therapeutics	-121.77%	N/A	-32.74%
Sensei Biotherapeutics	N/A	-1,012.17%	-175.69%

In the previous week, ADC Therapeutics had 2 more articles in the media than Sensei Biotherapeutics. MarketBeat recorded 10 mentions for ADC Therapeutics and 8 mentions for Sensei Biotherapeutics. ADC Therapeutics' average media sentiment score of 0.46 beat Sensei Biotherapeutics' score of 0.44 indicating that ADC Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ADC Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Sensei Biotherapeutics	0 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Sensei Biotherapeutics has lower revenue, but higher earnings than ADC Therapeutics. ADC Therapeutics is trading at a lower price-to-earnings ratio than Sensei Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ADC Therapeutics	$81.36M	1.70	-$142.62M	-$0.66	N/A
Sensei Biotherapeutics	N/A	N/A	-$21.08M	-$141.65	N/A

Summary

ADC Therapeutics beats Sensei Biotherapeutics on 9 of the 16 factors compared between the two stocks.

How does Sensei Biotherapeutics compare to InflaRx?

InflaRx (NASDAQ:IFRX) and Sensei Biotherapeutics (NASDAQ:FTH) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, dividends, profitability, analyst recommendations, media sentiment, earnings and valuation.

InflaRx has a beta of 2.48, suggesting that its stock price is 148% more volatile than the broader market. Comparatively, Sensei Biotherapeutics has a beta of -0.25, suggesting that its stock price is 125% less volatile than the broader market.

42.4% of InflaRx shares are owned by institutional investors. Comparatively, 10.5% of Sensei Biotherapeutics shares are owned by institutional investors. 16.3% of InflaRx shares are owned by company insiders. Comparatively, 7.0% of Sensei Biotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

InflaRx's return on equity of -53.56% beat Sensei Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
InflaRx	N/A	-53.56%	-43.02%
Sensei Biotherapeutics	N/A	-1,012.17%	-175.69%

In the previous week, Sensei Biotherapeutics had 6 more articles in the media than InflaRx. MarketBeat recorded 8 mentions for Sensei Biotherapeutics and 2 mentions for InflaRx. InflaRx's average media sentiment score of 0.71 beat Sensei Biotherapeutics' score of 0.44 indicating that InflaRx is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
InflaRx	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Sensei Biotherapeutics	0 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

InflaRx currently has a consensus price target of $7.33, indicating a potential upside of 254.27%. Sensei Biotherapeutics has a consensus price target of $54.90, indicating a potential upside of 67.53%. Given InflaRx's stronger consensus rating and higher probable upside, analysts clearly believe InflaRx is more favorable than Sensei Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InflaRx	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.88
Sensei Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83

Sensei Biotherapeutics has lower revenue, but higher earnings than InflaRx. InflaRx is trading at a lower price-to-earnings ratio than Sensei Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InflaRx	$30K	10,163.01	-$51.63M	-$0.58	N/A
Sensei Biotherapeutics	N/A	N/A	-$21.08M	-$141.65	N/A

Summary

InflaRx beats Sensei Biotherapeutics on 11 of the 15 factors compared between the two stocks.

How does Sensei Biotherapeutics compare to Equillium?

Sensei Biotherapeutics (NASDAQ:FTH) and Equillium (NASDAQ:EQ) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, dividends, profitability, media sentiment, risk and valuation.

In the previous week, Sensei Biotherapeutics had 1 more articles in the media than Equillium. MarketBeat recorded 8 mentions for Sensei Biotherapeutics and 7 mentions for Equillium. Equillium's average media sentiment score of 1.49 beat Sensei Biotherapeutics' score of 0.44 indicating that Equillium is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sensei Biotherapeutics	0 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Equillium	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

10.5% of Sensei Biotherapeutics shares are owned by institutional investors. Comparatively, 27.1% of Equillium shares are owned by institutional investors. 7.0% of Sensei Biotherapeutics shares are owned by insiders. Comparatively, 17.8% of Equillium shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Sensei Biotherapeutics has a beta of -0.25, meaning that its share price is 125% less volatile than the broader market. Comparatively, Equillium has a beta of 1.83, meaning that its share price is 83% more volatile than the broader market.

Sensei Biotherapeutics has higher earnings, but lower revenue than Equillium. Equillium is trading at a lower price-to-earnings ratio than Sensei Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sensei Biotherapeutics	N/A	N/A	-$21.08M	-$141.65	N/A
Equillium	$41.10M	3.82	-$22.40M	-$0.20	N/A

Equillium's return on equity of -41.15% beat Sensei Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sensei Biotherapeutics	N/A	-1,012.17%	-175.69%
Equillium	N/A	-41.15%	-38.29%

Sensei Biotherapeutics presently has a consensus price target of $54.90, indicating a potential upside of 67.53%. Equillium has a consensus price target of $7.57, indicating a potential upside of 205.30%. Given Equillium's stronger consensus rating and higher possible upside, analysts clearly believe Equillium is more favorable than Sensei Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sensei Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83
Equillium	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	2.91

Summary

Equillium beats Sensei Biotherapeutics on 11 of the 15 factors compared between the two stocks.

How does Sensei Biotherapeutics compare to NervGen Pharma?

NervGen Pharma (NASDAQ:NGEN) and Sensei Biotherapeutics (NASDAQ:FTH) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, earnings, media sentiment, analyst recommendations, profitability, risk and dividends.

10.5% of Sensei Biotherapeutics shares are owned by institutional investors. 7.0% of Sensei Biotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

NervGen Pharma currently has a consensus target price of $14.00, indicating a potential upside of 733.33%. Sensei Biotherapeutics has a consensus target price of $54.90, indicating a potential upside of 67.53%. Given NervGen Pharma's higher possible upside, analysts plainly believe NervGen Pharma is more favorable than Sensei Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NervGen Pharma	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	2.83
Sensei Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83

NervGen Pharma is trading at a lower price-to-earnings ratio than Sensei Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NervGen Pharma	N/A	N/A	-$31.58M	-$0.09	N/A
Sensei Biotherapeutics	N/A	N/A	-$21.08M	-$141.65	N/A

Sensei Biotherapeutics' return on equity of -1,012.17% beat NervGen Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NervGen Pharma	N/A	-1,259.82%	-199.79%
Sensei Biotherapeutics	N/A	-1,012.17%	-175.69%

In the previous week, Sensei Biotherapeutics had 1 more articles in the media than NervGen Pharma. MarketBeat recorded 8 mentions for Sensei Biotherapeutics and 7 mentions for NervGen Pharma. Sensei Biotherapeutics' average media sentiment score of 0.44 beat NervGen Pharma's score of 0.13 indicating that Sensei Biotherapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NervGen Pharma	0 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Sensei Biotherapeutics	0 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Sensei Biotherapeutics beats NervGen Pharma on 9 of the 12 factors compared between the two stocks.

Get Sensei Biotherapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FTH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

FTH vs. The Competition

Export

Metric	Sensei Biotherapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$835.68M	$3.74B	$7.03B	$13.06B
Dividend Yield	N/A	3.69%	2.56%	10.62%
P/E Ratio	-0.23	11.49	270.85	25.39
Price / Sales	N/A	1,270.12	597.90	88.46
Price / Cash	N/A	45.11	28.87	38.47
Price / Book	2.22	17.17	11.09	6.51
Net Income	-$21.08M	-$13.18M	$3.45B	$347.22M
7 Day Performance	14.70%	1.53%	0.74%	1.51%
1 Month Performance	26.67%	2.99%	2.15%	2.74%
1 Year Performance	N/A	56.69%	63.00%	21.07%

Sensei Biotherapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
FTH Sensei Biotherapeutics	4.4475 of 5 stars	$32.77 +1.3%	$54.90 +67.5%	N/A	$835.68M	N/A	N/A	40
ENTX Entera Bio	2.5186 of 5 stars	$3.00 -1.3%	$9.00 +200.0%	+44.5%	$149.84M	N/A	N/A	20	Gap Down
ADCT ADC Therapeutics	3.5051 of 5 stars	$1.19 +4.9%	$6.25 +427.4%	-68.0%	$143.73M	$81.36M	N/A	310	Earnings Report Analyst Upgrade
IFRX InflaRx	1.7262 of 5 stars	$2.00 +2.0%	$7.33 +266.7%	+136.4%	$141.69M	$30K	N/A	60
EQ Equillium	2.9858 of 5 stars	$2.23 +1.8%	$7.57 +239.5%	+107.0%	$138.47M	$41.10M	N/A	40	Positive News Earnings Report Analyst Upgrade High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:FTH) was last updated on 8/17/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Sensei Biotherapeutics (FTH) Competitors

FTH vs. ENTX, ADCT, IFRX, EQ, and NGEN

How does Sensei Biotherapeutics compare to Entera Bio?

Summary

How does Sensei Biotherapeutics compare to ADC Therapeutics?

Summary

How does Sensei Biotherapeutics compare to InflaRx?

Summary

How does Sensei Biotherapeutics compare to Equillium?

Summary

How does Sensei Biotherapeutics compare to NervGen Pharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FTH vs. The Competition

Sensei Biotherapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Sensei Biotherapeutics (FTH) Competitors

FTH vs. ENTX, ADCT, IFRX, EQ, and NGEN

How does Sensei Biotherapeutics compare to Entera Bio?

Does the media prefer ENTX or FTH?

Which has higher earnings and valuation, ENTX or FTH?

Which has more volatility & risk, ENTX or FTH?

Do institutionals & insiders hold more shares of ENTX or FTH?

Is ENTX or FTH more profitable?

Do analysts recommend ENTX or FTH?

Summary

How does Sensei Biotherapeutics compare to ADC Therapeutics?

Do analysts rate ADCT or FTH?

Which has more volatility & risk, ADCT or FTH?

Do insiders & institutionals have more ownership in ADCT or FTH?

Is ADCT or FTH more profitable?

Does the media refer more to ADCT or FTH?

Which has preferable earnings & valuation, ADCT or FTH?

Summary

How does Sensei Biotherapeutics compare to InflaRx?

Which has more risk & volatility, IFRX or FTH?

Do insiders and institutionals have more ownership in IFRX or FTH?

Is IFRX or FTH more profitable?

Does the media refer more to IFRX or FTH?

Do analysts recommend IFRX or FTH?

Which has preferable valuation and earnings, IFRX or FTH?

Summary

How does Sensei Biotherapeutics compare to Equillium?

Does the media favor FTH or EQ?

Do insiders & institutionals have more ownership in FTH or EQ?

Which has more risk & volatility, FTH or EQ?

Which has preferable earnings and valuation, FTH or EQ?

Is FTH or EQ more profitable?

Do analysts rate FTH or EQ?

Summary

How does Sensei Biotherapeutics compare to NervGen Pharma?

Do institutionals and insiders have more ownership in NGEN or FTH?

Do analysts rate NGEN or FTH?

Which has stronger valuation and earnings, NGEN or FTH?

Is NGEN or FTH more profitable?

Does the media prefer NGEN or FTH?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FTH vs. The Competition

Sensei Biotherapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools